SCHEMBL289165

SCHEMBL289165

N[C@H](Cc1ccc(Cl)c(Cl)c1)C(=O)O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 4/20 0.62
PTGS1 P23219 3/20 0.62
ALOX15 P16050 3/20 0.62
HIF1A Q16665 3/20 0.62
KDM4E B2RXH2 2/20 0.62
TDP1 Q9NUW8 2/20 0.62
USP2 O75604 1/20 0.62
EGFR P00533 1/20 0.62
LCK P06239 1/20 0.62
FYN P06241 1/20 0.62
ADORA3 P0DMS8 1/20 0.62
HTR2A P28223 1/20 0.62
PTGS2 P35354 1/20 0.62
RECQL P46063 1/20 0.62
HSD17B10 Q99714 1/20 0.62
PNMT P11086 1/20 0.58
KMO O15229 2/20 0.57
PKM P14618 2/20 0.56
ALPI P09923 1/20 0.56
XIAP P98170 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29397861 1.00 SLC7A5 (0.62) SLC7A5PTGS1ALOX15HIF1AKDM4E
SCHEMBL29478421 1.00 SLC7A5 (0.62) SLC7A5PTGS1ALOX15HIF1AKDM4E
SCHEMBL43915 1.00 SLC7A5 (0.62) SLC7A5PTGS1ALOX15HIF1AKDM4E
SCHEMBL43914 1.00 SLC7A5 (0.62) SLC7A5PTGS1ALOX15HIF1AKDM4E
SCHEMBL29778 0.86 SLC7A5 (0.73) SLC7A5PTGS1ALOX15HIF1AKDM4E
SCHEMBL157442 0.86 SLC7A5 (0.73) SLC7A5PTGS1ALOX15HIF1AKDM4E
SCHEMBL28512 0.86 SLC7A5 (0.73) SLC7A5PTGS1ALOX15HIF1AKDM4E
SCHEMBL1093972 0.86 SLC7A5 (0.58) SLC7A5PTGS1ALOX15HIF1AKDM4E
SCHEMBL29405778 0.86 SLC7A5 (0.73) SLC7A5PTGS1ALOX15HIF1AKDM4E
SCHEMBL1093973 0.86 SLC7A5 (0.58) SLC7A5PTGS1ALOX15HIF1AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 433 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4100064-A1 TARGETED PLASMA PROTEIN DEGRADATION Novartis AG (CH) 2022-12-14 EP claimed
CN-115335081-A Targeted plasma protein degradation 诺华股份有限公司 2022-11-11 CN claimed
US-20220306692-A1 PEPTIDE INHIBITORS OF FOCAL ADHESION KINASE ACTIVITY AND USES THEREOF ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA 2022-09-29 US claimed
EP-4021475-A1 PEPTIDE INHIBITORS OF FOCAL ADHESION KINASE ACTIVITY AND USES THEREOF Arizona Board of Regents on behalf of the University of Arizona (US) 2022-07-06 EP claimed
WO-2021156792-A1 TARGETED PLASMA PROTEIN DEGRADATION NOVARTIS AG (CH) 2021-08-12 WO claimed
WO-2021042064-A1 PEPTIDE INHIBITORS OF FOCAL ADHESION KINASE ACTIVITY AND USES THEREOF ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) 2021-03-04 WO claimed
US-10138270-B2 Synthetic peptide amides CARA THERAPEUTICS, INC. (US) 2018-11-27 US claimed
US-20180028594-A1 PERIPHERAL KAPPA OPIOID RECEPTOR AGONISTS FOR HARD TISSUE PAIN CARA THERAPEUTICS, INC. (US) 2018-02-01 US claimed
US-9695191-B2 Conformationally constrained, fully synthetic macrocyclic compounds POLYPHOR AG (CH) 2017-07-04 US claimed
US-20160362450-A1 SYNTHETIC PEPTIDE AMIDES CARA THERAPEUTICS, INC. (US) 2016-12-15 US claimed
US-20130012448-A1 SYNTHETIC PEPTIDE AMIDES CARA THERAPEUTICS, INC. (US) 2013-01-10 US claimed
EP-2064228-B1 SYNTHETIC PEPTIDE AMIDES CARA THERAPEUTICS INC (US) 2012-08-29 EP claimed
US-20120202821-A1 CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS POLYPHOR AG (CH) 2012-08-09 US claimed
US-8217007-B1 Synthetic peptide amides CARA THERAPEUTICS, INC. (US) 2012-07-10 US claimed
US-7727963-B2 Synthetic peptide amides CARA THERAPEUTICS, INC. (US) 2010-06-01 US claimed
EP-2064228-A2 SYNTHETIC PEPTIDE AMIDES Cara Therapeutics, Inc. (US) 2009-06-03 EP claimed
US-20090075907-A1 SYNTHETIC PEPTIDE AMIDES CARA THERAPEUTICS, INC. (US) 2009-03-19 US claimed
WO-2008057608-A2 SYNTHETIC PEPTIDE AMIDES CARA THERAPEUTICS, INC. (US) 2008-05-15 WO claimed
EP-1025127-A1 MSH-RECEPTOR SUBTYPE SELECTIVE CYCLIC PEPTIDES Wapharm AB (SE) 2000-08-09 EP claimed
WO-1998037097-A1 MSH-RECEPTOR SUBTYPE SELECTIVE CYCLIC PEPTIDES WAPHARM AB (SE) 1998-08-27 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120202821-A1 CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS HTR2B, MC1R, HTR1A SLC7A5 1600/4885PTGS1 109/4885ALOX15 1296/4885
US-10138270-B2 Synthetic peptide amides VIP, OPRK1, OPRL1 SLC7A5 201/4885PTGS1 164/4885ALOX15 1149/4885
US-20180028594-A1 PERIPHERAL KAPPA OPIOID RECEPTOR AGONISTS FOR HARD TISSUE PAIN OPRK1, OPRL1, OPRD1 SLC7A5 15/4885PTGS1 1124/4885ALOX15 650/4885
US-20090075907-A1 SYNTHETIC PEPTIDE AMIDES VIP, OPRK1, OPRL1 SLC7A5 201/4885PTGS1 164/4885ALOX15 1149/4885
US-20160362450-A1 SYNTHETIC PEPTIDE AMIDES VIP, OPRK1, OPRL1 SLC7A5 201/4885PTGS1 164/4885ALOX15 1149/4885
US-20220306692-A1 PEPTIDE INHIBITORS OF FOCAL ADHESION KINASE ACTIVITY AND USES THEREOF PTK2, LTK, LIMK2 SLC7A5 3035/4885PTGS1 3410/4885ALOX15 1485/4885
US-20130012448-A1 SYNTHETIC PEPTIDE AMIDES VIP, OPRK1, OPRL1 SLC7A5 201/4885PTGS1 164/4885ALOX15 1149/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.